GenMark Diagnostics Company Profile (NASDAQ:GNMK)

About GenMark Diagnostics

GenMark Diagnostics logoGenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GNMK
  • CUSIP:
Key Metrics:
  • Previous Close: $10.94
  • 50 Day Moving Average: $11.71
  • 200 Day Moving Average: $11.21
  • 52-Week Range: $46,404,000.00 - $4.66
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.61
  • P/E Growth: 7.55
  • Market Cap: $522.05M
  • Outstanding Shares: 46,404,000
  • Beta: 0.86
Profitability:
  • Net Margins: -98.17%
  • Return on Equity: -114.35%
  • Return on Assets: -66.62%
Debt:
  • Debt-to-Equity Ratio: 0.30%
  • Current Ratio: 3.26%
  • Quick Ratio: 3.05%
Additional Links:
Companies Related to GenMark Diagnostics:

Analyst Ratings

Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.25 (17.78% upside)

Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017Needham & Company LLCBoost Price TargetBuy$13.00 -> $15.00View Rating Details
1/23/2017Canaccord GenuitySet Price TargetBuy$14.00View Rating Details
9/16/2016Cowen and CompanyUpgradeMarket Perform -> Outperform$17.00View Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetOverweight$10.00 -> $13.00View Rating Details
2/26/2016Raymond James Financial, Inc.Lower Price TargetOutperform$9.00 -> $7.25View Rating Details
2/24/2016BTIG ResearchReiterated RatingBuy$9.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for GenMark Diagnostics (NASDAQ:GNMK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.27)$15.03 millionN/AView Earnings Details
11/3/2016Q316($0.31)($0.27)$10.36 million$10.80 millionViewN/AView Earnings Details
7/28/2016Q216($0.33)($0.30)$9.62 million$12.50 millionViewListenView Earnings Details
5/3/2016Q116($0.29)($0.30)$10.67 million$11.06 millionViewN/AView Earnings Details
2/23/2016Q415($0.27)($0.21)$12.34 million$13.20 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.27)$8.24 million$8.80 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.29)$7.59 million$7.65 millionViewN/AView Earnings Details
5/5/2015Q115($0.24)($0.24)$10.10 million$10.10 millionViewN/AView Earnings Details
2/24/2015Q414($0.28)($0.21)ViewN/AView Earnings Details
10/30/2014Q314($0.32)($0.23)$5.80 million$6.30 millionViewN/AView Earnings Details
8/11/2014Q214($0.29)($0.27)$4.79 million$6.55 millionViewN/AView Earnings Details
5/6/2014Q114($0.25)($0.21)$6.40 million$7.91 millionViewN/AView Earnings Details
3/11/2014Q413($0.22)($0.21)$6.06 million$6.45 millionViewN/AView Earnings Details
11/12/2013Q313($0.27)($0.24)$4.60 million$4.64 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.26)($0.25)$5.05 million$5.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$9.53 million$11.10 millionViewN/AView Earnings Details
11/10/2011($0.32)($0.31)ViewN/AView Earnings Details
8/5/2011($0.45)($0.39)ViewN/AView Earnings Details
5/9/2011($0.49)($0.56)ViewN/AView Earnings Details
3/3/2011($0.52)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GenMark Diagnostics (NASDAQ:GNMK)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS

Dividends

Dividend History for GenMark Diagnostics (NASDAQ:GNMK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for GenMark Diagnostics (NASDAQ:GNMK)
Insider Ownership Percentage: 7.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2017Hany MassaranyInsiderSell33,537$10.08$338,052.96View SEC Filing  
2/21/2017Jon Faiz KayyemSVPSell5,250$10.08$52,920.00View SEC Filing  
2/21/2017Scott MendelCFOSell8,595$10.08$86,637.60View SEC Filing  
2/2/2017Hany MassaranyInsiderSell1,142$11.58$13,224.36View SEC Filing  
2/2/2017Jennifer Anne WilliamsSVPSell332$11.58$3,844.56View SEC Filing  
2/2/2017Scott MendelCFOSell235$11.58$2,721.30View SEC Filing  
1/19/2017Hany MassaranyInsiderSell27,124$12.47$338,236.28View SEC Filing  
1/19/2017Michael GleesonSVPSell9,569$12.47$119,325.43View SEC Filing  
1/19/2017Scott MendelCFOSell9,098$12.47$113,452.06View SEC Filing  
12/5/2016Jennifer Anne WilliamsSVPSell336$11.31$3,800.16View SEC Filing  
12/2/2016Michael GleesonSVPSell357$11.30$4,034.10View SEC Filing  
11/22/2016Michael KagnoffDirectorBuy2,000$11.80$23,600.00View SEC Filing  
11/14/2016Michael KagnoffDirectorBuy2,000$12.50$25,000.00View SEC Filing  
11/2/2016Hany MassaranyInsiderSell1,148$10.30$11,824.40View SEC Filing  
11/2/2016Michael GleesonSVPSell400$10.30$4,120.00View SEC Filing  
9/7/2016Hany MassaranyInsiderSell1,186$8.69$10,306.34View SEC Filing  
9/7/2016Jennifer Anne WilliamsSVPSell523$8.69$4,544.87View SEC Filing  
9/2/2016Jon Faiz KayyemSVPSell133$8.62$1,146.46View SEC Filing  
8/29/2016Jennifer Anne WilliamsSVPSell24,172$8.63$208,604.36View SEC Filing  
8/22/2016Michael GleesonSVPSell7,500$9.00$67,500.00View SEC Filing  
8/12/2016Lisa M GilesDirectorBuy823$9.40$7,736.20View SEC Filing  
8/2/2016Eric StierSVPSell367$9.88$3,625.96View SEC Filing  
8/2/2016Hany MassaranyInsiderSell1,147$9.88$11,332.36View SEC Filing  
6/7/2016Hany MassaranyCEOSell1,188$8.98$10,668.24View SEC Filing  
6/7/2016Michael GleesonSVPSell868$8.80$7,638.40View SEC Filing  
6/3/2016Ingo ChakravartySVPSell184$8.53$1,569.52View SEC Filing  
5/9/2016Ingo ChakravartySVPSell582$5.42$3,154.44View SEC Filing  
5/2/2016Eric StierSVPSell363$5.79$2,101.77View SEC Filing  
5/2/2016Hany MassaranyCEOSell1,160$5.79$6,716.40View SEC Filing  
3/10/2016Michael KagnoffDirectorBuy2,500$4.90$12,250.00View SEC Filing  
3/7/2016Hany MassaranyCEOSell1,193$5.76$6,871.68View SEC Filing  
3/7/2016Michael GleesonSVPSell559$5.76$3,219.84View SEC Filing  
3/2/2016Eric StierSVPSell365$4.87$1,777.55View SEC Filing  
2/9/2016Ingo ChakravartySVPSell697$5.04$3,512.88View SEC Filing  
2/3/2016Hany MassaranyCEOSell9,173$4.99$45,773.27View SEC Filing  
2/3/2016Michael GleesonSVPSell3,083$4.99$15,384.17View SEC Filing  
1/21/2016Hany MassaranyCEOSell648$6.80$4,406.40View SEC Filing  
1/21/2016Michael GleesonSVPSell227$6.80$1,543.60View SEC Filing  
12/8/2015Eric StierSVPSell240$7.26$1,742.40View SEC Filing  
12/8/2015Hany MassaranyCEOSell1,735$7.26$12,596.10View SEC Filing  
12/3/2015Hany MassaranyCEOSell3,571$7.71$27,532.41View SEC Filing  
12/3/2015Michael GleesonSVPSell1,664$7.62$12,679.68View SEC Filing  
11/3/2015Lisa M GilesDirectorBuy4,000$6.60$26,400.00View SEC Filing  
10/30/2015Michael KagnoffDirectorBuy5,000$6.70$33,500.00View SEC Filing  
10/30/2015Scott MendelCFOBuy10,000$6.47$64,700.00View SEC Filing  
10/29/2015Daryl FaulknerDirectorBuy4,000$7.33$29,320.00View SEC Filing  
9/15/2015Jennifer Anne WilliamsSVPSell14,245$9.98$142,165.10View SEC Filing  
9/14/2015Jennifer Anne WilliamsSVPSell9,245$10.00$92,450.00View SEC Filing  
9/11/2015Hany MassaranyCEOSell1,683$9.64$16,224.12View SEC Filing  
9/11/2015Jennifer Anne WilliamsSVPSell18,280$9.99$182,617.20View SEC Filing  
9/4/2015Jennifer Anne WilliamsSVPSell1,867$9.59$17,904.53View SEC Filing  
9/2/2015Hany MassaranyCEOSell3,865$9.62$37,181.30View SEC Filing  
8/24/2015Scott MendelCFOBuy10,000$9.10$91,000.00View SEC Filing  
6/16/2015Hany MassaranyCEOSell1,698$9.12$15,485.76View SEC Filing  
6/4/2015Michael GleesonSVPSell1,595$9.55$15,232.25View SEC Filing  
6/3/2015Hany MassaranyCEOSell3,486$9.47$33,012.42View SEC Filing  
4/9/2015Hany MassaranyCEOSell5,942$11.52$68,451.84View SEC Filing  
3/13/2015Jennifer Anne WilliamsSVPSell30,000$12.56$376,800.00View SEC Filing  
3/11/2015Hany MassaranyCEOSell28,110$11.88$333,946.80View SEC Filing  
3/11/2015Jeffrey Alan HawkinsSVPSell6,832$12.01$82,052.32View SEC Filing  
3/10/2015Jennifer Anne WilliamsSVPSell722$11.83$8,541.26View SEC Filing  
3/10/2015Michael KagnoffDirectorBuy5,000$11.84$59,200.00View SEC Filing  
3/9/2015Ingo ChakravartySVPSell3,310$12.06$39,918.60View SEC Filing  
1/22/2015Hany MassaranyCEOSell5,982$12.88$77,048.16View SEC Filing  
1/7/2015Hany MassaranyCEOSell4,858$13.00$63,154.00View SEC Filing  
12/16/2014Kevin C OboyleDirectorSell291$12.40$3,608.40View SEC Filing  
12/15/2014Eric StierSVPSell235$12.51$2,939.85View SEC Filing  
12/15/2014Hany MassaranyCEOSell1,700$12.51$21,267.00View SEC Filing  
12/4/2014Hany MassaranyCEOSell3,300$12.06$39,798.00View SEC Filing  
12/4/2014Jeffrey Alan HawkinsSVPSell1,350$12.06$16,281.00View SEC Filing  
10/31/2014Jon Faiz KayyemSVPSell6,000$11.01$66,060.00View SEC Filing  
10/8/2014Hany MassaranyCEOSell5,804$9.00$52,236.00View SEC Filing  
10/7/2014Michael GleesonSVPSell55$9.10$500.50View SEC Filing  
9/12/2014Hany MassaranyCEOSell1,678$9.86$16,545.08View SEC Filing  
9/5/2014Hany MassaranyCEOSell3,795$10.04$38,101.80View SEC Filing  
9/5/2014Michael GleesonSVPSell1,833$10.04$18,403.32View SEC Filing  
8/7/2014Michael GleesonSVPSell52$11.15$579.80View SEC Filing  
7/1/2014Jon Faiz KayyemSVPSell6,000$13.60$81,600.00View SEC Filing  
6/11/2014Hany MassaranyCEOSell1,115$11.64$12,978.60View SEC Filing  
6/5/2014Jon Faiz KayyemSVPSell1,483$10.69$15,853.27View SEC Filing  
6/3/2014Hany MassaranyCEOSell2,700$10.67$28,809.00View SEC Filing  
5/29/2014Kevin C OboyleDirectorSell1,603$10.98$17,600.94View SEC Filing  
5/28/2014Jon Faiz KayyemSVPSell6,000$11.06$66,360.00View SEC Filing  
5/8/2014Richard SlanskyCFOSell2,302$9.26$21,316.52View SEC Filing  
4/9/2014Hany MassaranyCEOSell3,985$9.87$39,331.95View SEC Filing  
3/26/2014Jennifer Anne WilliamsSVPSell30,195$9.97$301,044.15View SEC Filing  
3/5/2014Jon Faiz KayyemSVPSell7,355$12.46$91,643.30View SEC Filing  
1/16/2014Jon Faiz KayyemSVPSell50,000$14.05$702,500.00View SEC Filing  
1/7/2014Hany MassaranyCEOSell4,698$13.31$62,530.38View SEC Filing  
12/6/2013Michael GleesonSVPSell2,211$11.14$24,630.54View SEC Filing  
12/4/2013Hany MassaranyCEOSell3,968$11.14$44,203.52View SEC Filing  
10/9/2013Hany MassaranyCEOSell3,925$12.05$47,296.25View SEC Filing  
10/1/2013Jon Faiz KayyemSVPSell6,000$12.14$72,840.00View SEC Filing  
9/4/2013Jeffrey Alan HawkinsSVPSell1,890$11.60$21,924.00View SEC Filing  
9/3/2013Hany MassaranyCEOSell2,354$11.60$27,306.40View SEC Filing  
9/3/2013Jon Faiz KayyemSVPSell1,545$11.60$17,922.00View SEC Filing  
8/20/2013Jon Faiz KayyemSVPSell1,310$10.15$13,296.50View SEC Filing  
7/1/2013Jon Faiz KayyemSVPSell6,000$10.40$62,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GenMark Diagnostics (NASDAQ:GNMK)
DateHeadline
4-traders.com logoGENMARK DIAGNOSTICS, INC. : Financial Statements and Exhibits (form 8-K) (NASDAQ:GNMK)
www.4-traders.com - February 25 at 5:19 PM
biz.yahoo.com logoGENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:GNMK)
biz.yahoo.com - February 24 at 6:45 PM
News IconThe Top 100 Developers of In-Vitro Diagnostics Tests for Infectious Diseases (NASDAQ:GNMK)
www.rnrmarketresearch.com - February 24 at 10:56 AM
marketexclusive.com logoInsider Trading Activity GenMark Diagnostics, Inc. (NASDAQ:GNMK) – insider Sold 33,537 shares of Stock (NASDAQ:GNMK)
marketexclusive.com - February 23 at 10:30 PM
4-traders.com logoInsider Trading Activity GenMark Diagnostics, Inc. (NASDAQ:GNMK) – CFO Sold 8,595 shares of Stock (NASDAQ:GNMK)
www.4-traders.com - February 22 at 5:44 PM
marketexclusive.com logoInsider Trading Activity GenMark Diagnostics, Inc. (NASDAQ:GNMK) – SVP Sold 5,250 shares of Stock (NASDAQ:GNMK)
marketexclusive.com - February 22 at 5:44 PM
News IconEquity Focus: Looking Closer at Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Sherwood Daily (NASDAQ:GNMK)
sherwooddaily.com - February 17 at 4:04 PM
finance.yahoo.com logoGenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call for February 28, 2017 (NASDAQ:GNMK)
finance.yahoo.com - February 9 at 6:15 PM
capitalcube.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January 31, 2017 (NASDAQ:GNMK)
www.capitalcube.com - January 31 at 6:09 PM
News IconTrading Insight: Taking a Look at Levels for GenMark Diagnostics Inc. (GNMK) - Market Point (NASDAQ:GNMK)
mtptnews.com - January 30 at 6:12 PM
News IconTechnical Updates on Shares of GenMark Diagnostics Inc. (GNMK) - Market Point (NASDAQ:GNMK)
mtptnews.com - January 27 at 4:59 AM
News IconLooking at the Numbers for GenMark Diagnostics, Inc. (NASDAQ:GNMK) - The Tribune (NASDAQ:GNMK)
lakecitytribune.com - January 26 at 6:57 PM
News IconNeedham Just Issued "Buy" Rating on GenMark Diagnostics Inc (GNMK) - Highland Mirror (NASDAQ:GNMK)
www.highlandmirror.com - January 25 at 4:15 AM
investornewswire.com logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Sales Predicted At $100.906 - Investor Newswire (NASDAQ:GNMK)
www.investornewswire.com - January 24 at 3:56 AM
News IconGenMark Diagnostics, Inc. (GNMK) Under Analyst Spotlight - UK Market News (NASDAQ:GNMK)
www.ukmarketnews.co.uk - January 19 at 7:12 PM
News IconToday's 13GD Alert: Why Jpmorgan Chase & Co Reported Big ... - Fair Herald (NASDAQ:GNMK)
fairherald.com - January 18 at 5:56 PM
News IconWill The Needle Move For GenMark Diagnostics, Inc. (NASDAQ:GNMK) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:GNMK)
wsbeacon.com - January 17 at 3:28 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Wall Street Beacon (NASDAQ:GNMK)
wsbeacon.com - January 14 at 5:29 PM
News IconStock Vaulting to Uncharted Territory: GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Wall Street Beacon (NASDAQ:GNMK)
wsbeacon.com - January 12 at 5:56 PM
streetinsider.com logoGenMark Diagnostics (GNMK) Preliminary Q4 Revenue Reported Essentially In-Line with Street - StreetInsider.com (NASDAQ:GNMK)
www.streetinsider.com - January 12 at 5:56 PM
thestreet.com logo7 Stocks Making Big Moves With Unusual Volume (NASDAQ:GNMK)
www.thestreet.com - January 11 at 6:03 PM
bizjournals.com logoThe Top 100 U.S. In-Vitro Diagnostics Companies (NASDAQ:GNMK)
www.bizjournals.com - January 10 at 6:24 PM
streetinsider.com logoGenMark Diagnostics (GNMK) Preliminary Q4 Revenue Reported Essentially In-Line with Street (NASDAQ:GNMK)
www.streetinsider.com - January 10 at 6:24 PM
News IconGenMark Diagnostics Release: Diagnostic Company Announces Preliminary Q4 2016 Financial Results (NASDAQ:GNMK)
www.biospace.com - January 10 at 6:24 PM
us.rd.yahoo.com logoGenMark Announces Preliminary Q4 2016 Financial Results (NASDAQ:GNMK)
us.rd.yahoo.com - January 10 at 6:24 PM
us.rd.yahoo.com logo8:08 am GenMark Diagnostics sees Q4 rev in-line (NASDAQ:GNMK)
us.rd.yahoo.com - January 10 at 6:24 PM
biz.yahoo.com logoGENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:GNMK)
biz.yahoo.com - January 10 at 6:24 PM
capitalcube.com logoGenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : January 10, 2017 (NASDAQ:GNMK)
www.capitalcube.com - January 10 at 6:24 PM
capitalcube.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January 9, 2017 (NASDAQ:GNMK)
www.capitalcube.com - January 9 at 4:17 PM
News IconAnalysts Watch GenMark Diagnostics, Inc. (GNMK) And Issue New Targets - NewsDen (NASDAQ:GNMK)
newsden.net - December 31 at 5:28 PM
finance.yahoo.com logoGenMark Diagnostics to Present at the 2017 J.P. Morgan Healthcare Conference (NASDAQ:GNMK)
finance.yahoo.com - December 28 at 5:25 PM
News IconGenMark Diagnostics Submits 510(k) Applications to the FDA for ePlex® Sample-to-Answer Instrument & Respiratory Pathogen Panel (NASDAQ:GNMK)
ih.advfn.com - December 22 at 10:46 PM
streetinsider.com logoGenMark Diagnostics (GNMK) Submits FDA 510(k) Applications for ePlex (NASDAQ:GNMK)
www.streetinsider.com - December 22 at 10:46 PM
streetinsider.com logoGenMark Diagnostics (GNMK) Submits FDA 510(k) Applications for ... - StreetInsider.com (NASDAQ:GNMK)
www.streetinsider.com - December 22 at 5:45 PM
finance.yahoo.com logo8:06 am GenMark Diagnostics submits 501(k) applications to the FDA for its for its ePlex sample-to-answer instrument and Respiratory Pathogen (NASDAQ:GNMK)
finance.yahoo.com - December 22 at 5:45 PM
publicnow.com logoGenMark Diagnostics Submits 510(k) Applications to the FDA for ePlex® Sample-to-Answer Instrument and Respiratory Pathogen Panel (NASDAQ:GNMK)
www.publicnow.com - December 22 at 5:45 PM
News IconTrading Focus: Eye on Shares of GenMark Diagnostics Inc. (GNMK) - StockTalk Daily (NASDAQ:GNMK)
stocktalkdaily.com - December 22 at 4:26 AM
News IconInvestor Radar: Focusing in on Shares of GenMark Diagnostics, Inc ... - OIB News (NASDAQ:GNMK)
oibnews.com - December 22 at 4:26 AM
News IconGenMark Diagnostics, Inc. (GNMK) Under Analyst Spotlight - UK ... - UK Market News (NASDAQ:GNMK)
www.ukmarketnews.co.uk - December 18 at 5:35 PM
News IconCompany Focus on Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Business Daily Leader (NASDAQ:GNMK)
businessdailyleader.com - December 18 at 5:34 PM
News IconInvestors are Keeping Tabs on GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Marion Business Daily (NASDAQ:GNMK)
marionbusinessdaily.com - December 18 at 5:34 PM
investornewswire.com logoStrong Sell Recommendations Of GenMark Diagnostics, Inc. (NASDAQ:GNMK) At 0 - Investor Newswire (NASDAQ:GNMK)
www.investornewswire.com - December 16 at 6:02 PM
investornewswire.com logoSentiments And Ratings Alert: GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Investor Newswire (NASDAQ:GNMK)
www.investornewswire.com - December 16 at 6:02 PM
capitalcube.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : December 16, 2016 (NASDAQ:GNMK)
www.capitalcube.com - December 16 at 6:02 PM
News IconInside the Numbers on Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) - OIB News (NASDAQ:GNMK)
oibnews.com - December 16 at 4:09 AM
News IconMF Rank in Focus for GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Liberty News (NASDAQ:GNMK)
libertynewsrecord.com - December 15 at 4:15 AM
News IconVC Score In Focus for GenMark Diagnostics, Inc. (NASDAQ:GNMK) - Marion Business Daily (NASDAQ:GNMK)
marionbusinessdaily.com - December 15 at 4:15 AM
News IconTrading Watch: Checking in on Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) - The Business Journal (NASDAQ:GNMK)
belmontbusinessjournal.com - December 13 at 4:31 PM
News IconInvestor Focus on Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) - OIB News (NASDAQ:GNMK)
oibnews.com - December 13 at 4:31 PM
capitalcube.com logoETFs with exposure to GenMark Diagnostics, Inc. : December 13, 2016 (NASDAQ:GNMK)
www.capitalcube.com - December 13 at 4:31 PM

Social

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?

5 analysts have issued 1-year price targets for GenMark Diagnostics' shares. Their predictions range from $7.25 to $17.00. On average, they anticipate GenMark Diagnostics' share price to reach $13.25 in the next twelve months.

When will GenMark Diagnostics announce their earnings?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:

  • According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/26/2017)

  • Needham & Company LLC analysts commented, "On 1/10/17, GNMK preannounced in line 4Q16 revenue and disclosed that it ended 2016 with 55 customer agreements for over 85 ePlex instruments. And on 12/22/16, GNMK announced that it had submitted its 510(k) to the FDA for its ePlex and Respiratory Pathogen Panel; we expect GNMK to launch ePlex in the U.S. in mid-2017. bioMerieux continues to see very strong growth with its FilmArray platform and we think this bodes well for the ePlex launch. We expect the ePlex launch to cause GNMK's revenue growth to accelerate during 2017, and we reiterate our Buy rating." (1/24/2017)

Who owns GenMark Diagnostics stock?

GenMark Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Putnam Investments LLC (8.80%), Artisan Partners Limited Partnership (4.07%), State Street Corp (1.58%), FIL Ltd (0.95%) and Thrivent Financial for Lutherans (0.64%). Company insiders that own GenMark Diagnostics stock include Daryl Faulkner, Eric Stier, Hany Massarany, Ingo Chakravarty, Jeffrey Alan Hawkins, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel.

Who sold GenMark Diagnostics stock? Who is selling GenMark Diagnostics stock?

GenMark Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Artisan Partners Limited Partnership, Alyeska Investment Group L.P., Two Sigma Investments LP and Allianz Asset Management AG. Company insiders that have sold GenMark Diagnostics stock in the last year include Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson and Scott Mendel.

Who bought GenMark Diagnostics stock? Who is buying GenMark Diagnostics stock?

GenMark Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial for Lutherans, State Street Corp, Russell Investments Group Ltd., Baird Financial Group Inc., A.R.T. Advisors LLC, AQR Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought GenMark Diagnostics stock in the last two years include Daryl Faulkner, Lisa M Giles, Michael Kagnoff and Scott Mendel.

How do I buy GenMark Diagnostics stock?

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GenMark Diagnostics stock cost?

One share of GenMark Diagnostics stock can currently be purchased for approximately $11.25.

GenMark Diagnostics (NASDAQ:GNMK) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Earnings History Chart

Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Dividend History Chart

Dividend Payments by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Last Updated on 2/26/2017 by MarketBeat.com Staff